Image-Based Analysis of Tumor Localization After Intra-Arterial Delivery of Technetium-99m-Labeled SPIO Using SPECT/CT and MRI

In Joon Lee, MD, PhD¹, Ji Yong Park, MS²,³, Young-il Kim, MD, PhD²,⁴, Yun-Sang Lee, PhD²,⁴, Jae Min Jeong, PhD², Jaeil Kim, BS², Eui Shin Edmund Kim, MD, PhD⁴,⁵, Keon Wook Kang, MD, PhD², Dong Soo Lee, MD, PhD²,⁴, Seonji Jeong, MD⁶, Eun Jeong Kim, BS⁶, Young Il Kim, MD, PhD⁶,⁷, and Jin Wook Chung, MD, PhD⁶

Abstract
The aim of this study is to evaluate the localization of ⁹⁹mTc-labeled dextran-coated superparamagnetic iron oxide (SPIO) nanoparticles to the liver tumor using image-based analysis. We delivered ⁹⁹mTc-SPIO intravenously or intra-arterially (IA) with/without Lipiodol to compare the tumor localization by gamma scintigraphy, single-photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI) in a rabbit liver tumor. The gamma and SPECT image-based analysis shows that the uptake ratio of the tumor to the normal liver parenchyma is highest after delivery of ⁹⁹mTc-SPIO with Lipiodol IA and that well correlates with the trend of the signal decrease in the liver MRIs. Intra-arterial delivery of SPIO with Lipiodol might be a good drug delivery system targeting the hepatic tumors, as confirmed by image-based analysis.

Keywords
Intra-arterial (IA) delivery, technetium-99m, single-photon emission computed tomography (SPECT), superparamagnetic iron oxide (SPIO), magnetic resonance imaging (MRI)

Introduction
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world.¹ The majority of patients diagnosed in intermediate or advanced stages are not amendable to curative resection.² Currently, tranarterial chemoembolization (TACE) is the primary therapeutic option for the intermediate stage, which includes asymptomatic multifocal or large HCC according to the Barcelona Clinic Liver Cancer Classification.³,⁴ Conventional TACE traditionally means that iodized oil is mixed with an anticancer drug and infused through the feeding artery of the HCC.⁵,⁶ Ideally, the iodized oil acts like a drug-releasing carrier; therefore, it should be retained in the tumor tissue for a certain time to gradually release the anticancer drug within the tumor. Still, a significant amount of the infused anticancer drug passes into systemic circulation, which may cause systemic side effects.⁷,⁸

Superparamagnetic iron oxide (SPIO) is one class of magnetic nanoparticles that can play a role in drug-releasing nanocarriers, as well as serve as magnetic resonance imaging (MRI)
contrast agents for clinical diagnosis.\textsuperscript{9-13} Ferumoxide has been approved for use as a negative contrast agent in liver MRI because it creates a strong signal decrease in the normal liver parenchyma on the T2-weighted MRI.\textsuperscript{14-16} A mixture of sticky oil, such as Lipiodol, and an anticancer drug-loaded ferumoxide could have pharmacokinetic advantages as well as being useful for the monitoring of the intratumoral accumulation of the infused mixture both by computed tomography (CT) and MRI.\textsuperscript{17} However, that study had the lack of quantification data of the ferumoxide after IA delivery to liver tumor, even though this drug delivery system was a newly established one. Without knowing its whole-body distribution and pharmacokinetics, it is impossible to know how and where ferumoxide is distributed in the body after IA delivery.

A recent experimental study reported that it was also able to act as a drug-releasing nanocarrier and could be applied as an intra-arterial (IA) drug delivery system in the TACE of the HCC.\textsuperscript{17} A mixture of sticky oil, such as Lipiodol, and an anticancer drug-loaded ferumoxide could have pharmacokinetic advantages as well as being useful for the monitoring of the intratumoral accumulation of the infused mixture both by computed tomography (CT) and MRI.\textsuperscript{17} However, that study had the lack of quantification data of the ferumoxide after IA delivery to liver tumor, even though this drug delivery system was a newly established one. Without knowing its whole-body distribution and pharmacokinetics, it is impossible to know how and where ferumoxide is distributed in the body after IA delivery.

A traditional biodistribution study of newly developed particles conventionally is carried out by sequentially killing the experimental animals at multiple time points after particle injection and measuring the amount of injected particles in each major organ. Several decades ago, ferumoxide was also evaluated using this method in clinical trials.\textsuperscript{18} If particles can be labeled by a radioisotope, the image-based analysis of the localization of those particles could be demonstrated on nuclear medicine imaging modalities, such as gamma scintigraphy, single-photon emission computed tomography (SPECT), or positron emission tomography.

Research on radioisotope-labeled nanoparticles includes the monitoring of the in vivo behavior of nanoparticles to evaluate the feasibility of an in vivo application of those nanoparticles.\textsuperscript{19-23} Through nuclear medicine imaging, the accumulation of nanoparticles in tumors and major organs at every time point could be obtained noninvasively and quantitatively. Technetium-99m is one of the commonly used radioisotopes in nuclear medicine with a 6-hour half-life, 140 keV gamma energy, and a generator-eluted radioisotope, which feature the most convenient method for clinical routines.\textsuperscript{24} Referring to previous research on 99mTc-labeled dextran derivatives, we modified and used this method for radiolabeling of SPIO.\textsuperscript{25}

In this study, we synthesized 99mTc-labeled SPIO and delivered those nanoparticles to liver tumor–bearing rabbits intravenously (IV) or IA with/without Lipiodol and compared the tumor localization of those particles using image-based analysis.

**Materials and Methods**

**General**

Commercially available dextran-coated SPIO nanoparticles (MR contrast agent, Feridex IV, core size: 5-10 nm, overall size: 100-250 nm; Advanced Magnetics, Cambridge, Massachusetts) were used for this experiment.\textsuperscript{26} Lipiodol was purchased from Andre Guerbet (Aulnay-sous-Bois, France) and a desalting column was from GE Healthcare Bio-Sciences Corp (PD-10, Sephadex G-25 Medium, New Jersey). Tiletamine–zolazepam (Zoletil 50; Virbac, Carros, France) and xylazine hydrochloride (Rompun; Bayer, Seoul, South Korea) were used for anesthetic agents. 99Mo-99mTc generator (Samyong Unitech Co, Seoul, South Korea) was used for 99mTc elution. A microcatheter (Progreat; Terumo, Tokyo, Japan) was used for IA delivery procedures.

All other reagents were purchased from Sigma-Aldrich Korea (Gyeonggi Province, South Korea) and were used without further purification. Particle size distribution was measured by nanotrack analysis (NTA) method using a NANOSIGHT instrument (Malvern, United Kingdom). The radiolabeling yield or the purity of the 99mTc-SPIO was checked by thin-layer chromatography (TLC) using ITLC-SG (Agilent Technologies, Lake Forest City, California) as a stationary phase and acetone or 0.1 M citrate solution as a mobile phase. Radio chromatograms were obtained using an AR2000 TLC scanner (Bioscan, Washington, DC). Magnetic resonance images were obtained using a 3.0-T Tim Trio clinical MRI scanner (Siemens Healthcare, Erlangen, Germany), and images were analyzed on a Picture Archiving and Communications System (PACS) workstation (m-view; Marotech, Seoul, Korea); SPECT/CT images and scintigraphy images were obtained using a GE Discovery model NM/CT 670 instrument (GE Healthcare, Milwaukee, Wisconsin). Visipaque 270 (GE Healthcare Ireland, Cork, Ireland) was used as CT contrast media. SPSS version 16.0 (SPSS, Inc. an IBM Company, Chicago, Illinois) was used for statistical analysis.

![Figure 1. Overview of the experimental design.](image-url)
The study was approved both by the Institutional Animal Care and Use Committee (No. 13-0059) and the Institutional Biosafety Committee (No. 1303-006-004) at Seoul National University Hospital.

**Study Design and Animal Model**

The scheme of the experimental design is shown in Figure 1. Adult New Zealand white rabbit was selected as an experimental model of liver cancer. VX2 carcinoma is an anaplastic squamous cell carcinoma derived from a virus-induced papilloma in rabbits, and we selected the rabbit VX2 liver tumor model as an experimental model in this study, which is widely known for well-established animal model for the study of TACE because its blood supply is similar to that of HCC. The VX2 carcinoma strain was maintained in the right hind limb of a carrier rabbit by deep intramuscular injection throughout the study.27,28

A total of 12 rabbits weighing 3.0 to 3.5 kg were raised in rooms with a 12-hour light/dark cycle and a constant temperature (23°C ± 2°C). One rabbit was missed by overdose of anesthetic agent. Anesthesia was induced with an intramuscular injection of 5 mg/kg body weight tiletamine–zolazepam and anesthetic agent. Anesthesia was induced with an intramuscular injection of 5 mg/kg body weight tiletamine–zolazepam and 2 mg/kg body weight 2% xylazine hydrochloride for all procedures. The left lobe of the liver was exposed through a midline incision in the abdominal wall, and a small piece of tumor (1 mm³, VX2 carcinoma) was directly implanted at the subcapsular area.17,29 Tumor formation was confirmed by MRI (1 mm³, VX2 carcinoma) was directed implanted at the subcapsular area.17,29 Tumor formation was confirmed by MRI (1 mm³, VX2 carcinoma) was directly implanted at the subcapsular area.17,29 Tumor formation was confirmed by MRI (1 mm³, VX2 carcinoma) was directly implanted at the subcapsular area.17,29 Tumor formation was confirmed by MRI (1 mm³, VX2 carcinoma) was directly implanted at the subcapsular area.17,29 Tumor formation was confirmed by MRI (1 mm³, VX2 carcinoma) was directly implanted at the subcapsular area.17,29 Tumor formation was confirmed by MRI (1 mm³, VX2 carcinoma) was directly implanted at the subcapsular area.17,29 Tumor formation was confirmed by MRI (1 mm³, VX2 carcinoma) was directly implanted at the subcapsular area.17,29 Tumor formation was confirmed by MRI (1 mm³, VX2 carcinoma) was directly implanted at the subcapsular area.17,29 Tumor formation was confirmed by MRI.
Intra-Arterial Delivery Procedure

All IA delivery procedures were performed by an interventional radiologist. An 18-gauge IV catheter was inserted into the right auricular artery, and a microcatheter was advanced through this route to the descending aorta and celiac axis. Hepatic arteriography was performed to identify the tumor location and its feeder from the left hepatic artery. After the microcatheter was successfully navigated to the feeder, the materials prepared for the particular study group were carefully infused while avoiding retrograde reflux into the right hepatic artery.

Gamma Scintigraphy and SPECT/CT Image Acquisition and Analysis

After the delivery of $^{99m}$Tc-SPIO (200 μL, 0.25 mg Fe/kg, 2.55 ± 0.04 MBq), the animals were placed into a SPECT/CT scanner and immediately underwent a dynamic scan with a gamma scintigraphy image using 1-minute time frames for 20 minutes. Static scintigraphy images were obtained at 60 and 180 minutes after the delivery. The gamma scintigraphy images were acquired with a low-energy, high-resolution collimator (10% window centered at 140 keV, ×1.28 zoom, and a 256 × 256 matrix) using the step-and-shoot scan mode. Single-photon emission computed tomography/CT scanning was performed 90 minutes after the delivery of $^{99m}$Tc-SPIO for each group. Computed tomography and SPECT images were acquired for 10 and 20 minutes, respectively. Computed tomography scanning was performed using the following parameters: 16 × 0.625 mm detector configuration, a rotation time of 1 second, 0.562 pitch, 120 kVp, 30 mAs, 1.25-mm slice thickness with no gap, and 512 × 512 matrix size. Single-photon emission computed tomography images were taken using a low-energy, high-resolution collimator, 10% window centered at 140 keV, 2-mm slice thickness, ×1.0 zoom, and a
128 × 128 matrix with the step-and-shoot scan mode. Gamma scintigraphy and SPECT/CT images were reconstructed by the ordered subset expectation maximization (iteration = 2, subset = 10) with a Butterworth filter (frequency = 0.48, power = 10). The fusion of the SPECT and CT images was performed automatically by the software.

For the analyses of the SPECT/CT images, a nuclear medicine physician drew a volume of interest (VOI) for the CT-matched tumor lesion for maximum tumor count identification using the GE workstation. A VOI of normal liver parenchyma was also drawn and confirmed the mean count as background. For gamma scintigraphy image analysis, a nuclear medicine physician drew a region of interest (ROI) for SPECT/CT-matched tumor lesion area and checked the maximum tumor count. The ROI of normal liver parenchyma was drawn and verified the mean count as background.

The CT images were evaluated on the same workstation by a radiologist. The high attenuated lesions in the tumors suggested iodized oil accumulation. The CT attenuation values of the iodized oil accumulated in the tumor and normal liver parenchyma were measured.

**Pathological Analysis**

Experimental animals were killed using IV injection of a lethal amount (7-10 mL) of xylazine hydrochloride under
deep anesthesia. Livers were carefully removed, the tumors and the right hemiliver parenchyma were placed in a bottle containing 5% formalin and subsequently treated with hematoxylin and eosin staining for basic histopathological examinations, and then Prussian blue staining was applied to confirm SPIO deposition.

Statistical Analysis

Data processing and analysis were performed using SPSS version 16.0. The Kruskal-Wallis test was conducted to compare the tumor size and the uptake ratio of the tumor to normal liver parenchyma on the gamma scintigraphy images and SPECT/CT images. The Mann-Whitney test was used for 1-to-1 group comparisons as a post hoc test of the nonparametric test. Two-tailed P values <.05 were considered as statistically significant.

Results

Characterization of $^{99m}$Tc-SPIO

The size of the SPIO, the modified SPIO, and the $^{99m}$Tc-SPIO were measured by NTA to be 158 ± 60 nm, 168 ± 67 nm, and 155 ± 65 nm, respectively (Figure 2B). The labeling efficiency as well as radiochemical purity of $^{99m}$Tc-SPIO was measured by radio-TLC to be >95% (Figure 2C). The final Fe amount and radioactivity of $^{99m}$Tc-SPIO, which was injected into each rabbit, were calculated to be 0.25 mg Fe/kg and 2.55 ± 0.04 MBq. The stability of $^{99m}$Tc-SPIO in human serum at 37°C was checked by radio-TLC and over 90% for 2 hours (data were not shown).

$^{99m}$Tc-SPIO Scintigraphy and SPECT/CT Image-Based Analysis

Figure 3 presents representative scintigraphy, SPECT/CT, and MRIs for each group. Group C shows the highest tumor uptake of $^{99m}$Tc-SPIO among the studied groups in scintigraphy images and SPECT/CT images, and persistent retention can be observed from the initial image to the image taken at 180 minutes (Figure 3A and B). The tumor-to-normal liver parenchyma uptake ratios on SPECT/CT images were significantly different between all 3 groups and ranged in the order of C > B > A (Kruskal-Wallis test, $P < .05$; Figure 4A), which correlated well with the signal decrease trend shown on the liver MRIs (Figure 5). On the CT images, only group C showed iodized oil uptake in the tumor (Figure 3B).

Signal Intensity of Tumors in MRI

Measured diameters of the tumors were 1.8 ± 0.61 cm (mean ± standard deviation [SD]) for group A, 1.6 ± 0.17 cm for group B, and 1.6 ± 0.32 cm for group C. There was no significant difference in tumor size among the groups ($P = .919$).
In T2*-weighted gradient-echo images, group C showed the highest signal decrease after 99mTc-SPIO delivery to the tumor tissue; in contrast, group A showed no significant MR signal change after 99mTc-SPIO delivery (Wilcoxon rank sum test, $P = 1.0$; Figure 3D).

In comparison between groups A, B, and C, there were no differences in the first set of MRIs, but the signal/intensity ratio was significantly different between groups for second MRIs (Kruskal-Wallis test, $P < .05$ for the second MRIs, $P > .1$ for the first MRIs; Figure 5). According to the relative tumor–back muscle signal intensity ratio, group C exhibited the most signal decrease in the tumor on second MRIs and there were significant differences in group C versus groups B and A ($P < .001$; Figure 5).

**Pathological Examination**

In groups B and C, Prussian blue–positive vesicles (indicating the presence of Fe$^{2+}$ ions) were identified around tumor vessels, and in a few tumor cells, a septum within the tumor and a capsule of the tumor (Figure 6). Group C had Prussian blue–positive lesions more frequently than group B, mainly around the tumor vessels. However, no Prussian blue–positive lesions were observed in the tumors of group A. In the right hemiliver parenchyma of all of the groups, a few cells contained Prussian blue–positive vesicles representing Kupffer cells were identified.

**Discussion**

Radioisotope-labeled nanoparticles may be used for multimodal imaging to overcome the limitations of each imaging modality. We used 99mTc-SPIO as a multimodal imaging agent to evaluate the biodistribution of dextran-coated SPIO nanoparticles allowing to acquire sensitive and quantitative SPECT data and high spatial resolution MRI images.

Dextran-coated SPIO nanoparticles were successfully modified using a ring-opening reaction of a glucose moiety of dextran for the conjugation of cysteamine, and a sodium borohydride reduced Schiff base to the secondary amine, and finally, we obtained the chelator-modified SPIO for 99mTc labeling. The size of the SPIO did not significantly change after surface modification and radiolabeling; therefore, we expected that the tumor localization pattern of the SPIO and 99mTc-SPIO would be the same. Technetium-99m labeling of the modified SPIO was performed using the conventional method (SnCl$_2$-reducing agent). Labeling efficiency and radiochemical purity were measured by radio-TLC to be over 95%. In the radio-TLC, 99mTc-SPIO moved with the solvent front ($R_f$ value: 1.0), whereas the 99mTc-tin-colloid remained at the origin ($R_f$ value: 0) in the 0.1 M citrate eluent (Figure 2C). The final product contained less than 2% of 99mTc-tin-colloid and was used without further purification.

As a result, sequential, noninvasive, and quantitative tumor localization assessment was achieved using the various...
delivery methods. Our method can be applied in an image-based tumor localization analysis of newly developed SPIO agents.

The uptake ratio of tumor to normal liver calculated from the scintigraphy images was more than 1 in group A (Figure 4B), whereas from SPECT/CT, data were less than 1 (Figure 4A). We believe that the overlap of the normal liver parenchyma with the tumor hampers the exact evaluation of the 99mTc-SPIO distribution by gamma scintigraphy. Future studies of newly developed SPIO should include SPECT/CT imaging for accurate analyses.

The average size of the 99mTc-SPIO was 155 nm and much smaller than liver capillary, thus 99mTc-SPIO could easily leak from the tumor after IA delivery. In this study, group C (IA delivery with Lipiodol) had the highest tumor retention among 3 groups according to 99mTc-SPIO scintigraphy, SPECT/CT, and MRIs. And also more iron depositions or Fe ions were found, mainly around the perivascular structures on the pathology slides. The iodized oil blocks the blood flow of the tumor-feeding artery in chemoembolization, which may result in better SPIO retention in the tumor, especially around the tumor vessels. Moreover, for hypervascular tumors, the blockage of tumor-feeding arteries creates ischemia of the tumor and results in necrosis; therefore, a combination of SPIO and Lipiodol in the IA delivery system can maximize drug delivery to the tumor and consequently the therapeutic response.

Evaluating the accumulation of the chemoembolic materials in the tumor is important, because it allows prediction of the therapeutic response. Computed tomography scans are usually used for evaluation after chemoembolization with Lipiodol, because the iodized oil has a strong CT contrast. Recently, MRI has been widely used as the imaging modality of choice in patients with liver cancers, because it can detect HCC better than CT. However, it is hard to detect Lipiodol deposition on MRIs because of the vague signal intensity changes in the tumor. In this study, we could monitor the delivery of chemoembolic materials (99mTc-SPIO with Lipiodol, group C) by fluoroscopy guidance and by nuclear medicine imaging modalities, CT, MRI, or multimodal detection.

In this study, we observed that normal liver had slight signal decreases in liver MRIs and diffuse uptake on scintigraphy and SPECT images at 3 hours after IA delivery of 99mTc-SPIO with or without Lipiodol. That may result from the deposition of SPIO passing into the systemic circulation. Feridex could easily be taken up in healthy liver and spleen tissues. Therefore, off-target delivery also should be considered in future studies, as this effect could be problematic because of potential hepatotoxicity. The kidneys and bladders also show diffuse uptake on 99mTc-SPIO scintigraphy and SPECT images, but there is no signal decrease for MRIs. Referring to the literature, Feridex is seldom retained in these organs. Therefore, this uptake might not be related to the deposition of SPIO. As the thyroid gland did not show high uptake, the diffuse uptake is also not related to free 99mTc. In our speculation, the kidney and bladder uptake might come from the detached 99mTc-chelator moiety, not from the free 99mTc, by the degradation of the 99mTc-chelator moiety on the surface of the SPIO, which would be excreted through urinary tract.

In conclusion, we successfully demonstrated the image-based tumor localization of 99mTc-SPIO in VX2 tumor model, and the IA delivery of SPIO/Lipiodol mixture was confirmed to be a potential drug delivery system targeting liver tumors.

Authors' Note
Informed consent was obtained from all individual participants included in the study. The first three authors contributed equally to this work.

Acknowledgments
The authors acknowledge Dr Lojos Balogh for help with the revision of this manuscript.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a grant from the Korean Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI12C1148, HI14C1277 and HI15C3093), and the National Research Foundation of Korea (NRF-2015M2A2A7062450).

References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
2. Kim YI, Park JW, Kwak HW, et al. Long-term outcomes of second treatment after initial transarterial chemoembolization in patients with hepatocellular carcinoma. Liver Int. 2014;34(8):1278–1286.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–1236.
4. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–1255.
5. Johnson PJ, Kalayci C, Dobbs N, et al. Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. J Hepatol. 1991;13(1):120–127.
6. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46(3):474–481.
9. Cole AJ, Yang VC, David AE. Cancer theranostics: the rise of targeted magnetic nanoparticles. *Trends Biotechnol.* 2011;29(7):323–332.

10. Ittrich H, Peldschus K, Raabe N, Kaul M, Adam G. Superparamagnetic iron oxide nanoparticles in biomedicine: applications and developments in diagnostics and therapy. *Rofo.* 2013;185(12):1149–1166.

11. Sun C, Lee JS, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. *Adv Drug Deliv Rev.* 2008;60(11):1252–1265.

12. Veiseh O, Gunn JW, Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. *Adv Drug Deliv Rev.* 2010;62(3):284–304.

13. Zhang XY, Robledo BN, Harris SS, Hu XP. A bacterial gene, mms6, as a new reporter gene for magnetic resonance imaging of mammalian cells. *Mol Imaging.* 2014;13.

14. Stark DD, Weissleder R, Elizondo G, et al. Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. *Radiology.* 1988;168(2):297–301.

15. Oswald P, Clement O, Chambon C, Schouman-Claeys E, Frijga G. Liver positive enhancement after injection of superparamagnetic nanoparticles: respective role of circulating and uptaken particles. *Magn Reson Imaging.* 1997;15(9):1025–1031.

16. Benderbous S, Corot C, Jacobs P, Bonnemain B. Superparamagnetic agents: physicochemical characteristics and preclinical imaging evaluation. *Acad Radiol.* 1996;3(suppl 2):S292–S294.

17. Lee IJ, Ahn CH, Cha EJ, Chung JJ, Chung JW, Kim YI. Improved drug targeting to liver tumors after intra-arterial delivery using superparamagnetic iron oxide and iodized oil: preclinical study in a rabbit model. *Invest Radiol.* 2013;48(12):826–833.

18. Weissleder R, Stark DD, Engelstad BL, et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. *AJR Am J Roentgenol.* 1989;152(1):167–173.

19. de Rosales RTM, Tavare R, Glaria A, Varma G, Protti A, Blower PJ. Tc-99m-bisphosphonate-iron oxide nanoparticle conjugates for dual-modality biomedical imaging. *Bioconjug Chem.* 2011;22(3):455–465.

20. Lee HY, Li Z, Chen K, et al. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. *J Nucl Med.* 2008;49(8):1371–1379.

21. Lee YK, Jeong JM, Roigebazar L, et al. Nanoparticles modified by encapsulation of ligands with a long alkyl chain to affect multi-specific and multimodal imaging. *J Nucl Med.* 2012;53(9):1462–1470.

22. Madru R, Kjellman P, Olsson F, et al. 99mTc-labeled superparamagnetic iron oxide nanoparticles for multimodality SPECT/MRI of sentinel lymph nodes. *J Nucl Med.* 2012;53(3):459–463.

23. Yang X, Hong H, Grazier JJ, et al. cRGD-functionalized, DOX-conjugated, and (6)(4)Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. *Biomaterials.* 2011;32(17):4151–4160.

24. Schwochau K. Technetium radiopharmaceuticals—fundamentals, synthesis, structure, and development. *Angew Chem Int Ed Engl.* 1994;33(22):2258–2267.

25. Matsuura K, Harasawa K, Imamura T, Fujikata T, Takata J, Karube Y. Technetium labeling of dextran incorporating cysteamine as a ligand. *Nucl Med Biol.* 2005;32(3):279–285.

26. Jung CW, Jacobs P. Physical and chemical properties of superparamagnetic iron oxide Mr contrast agents—ferumoxides, ferumoxtran, ferumoxsil. *Magn Reson Imaging.* 1995;13(5):661–674.

27. Guo Y, Zhang Y, Jin N, et al. Electroporation-mediated transcatheter arterial chemoembolization in the rabbit VX2 liver tumor model. *Invest Radiol.* 2012;47(2):116–120.

28. Kim YI, Chung JW, Park JH, Han JK, Hong JW, Chung H. Intraarterial drug delivery in rabbit hepatic tumors: transfection with nonviral vector by using iodized oil emulsion. *Radiology.* 2006;240(3):771–777.

29. Kim KW, Lee JM, Kim JH, et al. CT color mapping of the arterial enhancement fraction of VX2 carcinoma implanted in rabbit liver: comparison with perfusion CT. *AJR Am J Roentgenol.* 2011;196(1):102–108.

30. Jeong JM, Hong MK, Kim YJ, et al. Development of Tc-99m-neomannosyl human serum albumin (Tc-99m-MSA) as a novel receptor binding agent for sentinel lymph node imaging. *Nucl Med Commun.* 2004;25(12):1211–1217.

31. Chang IS, Lee MW, Kim YI, et al. Comparison between transauricular and transfemoral arterial access for hepatic artery angiography in a rabbit model. *J Vasc Interv Radiol.* 2011;22(8):1181–1187.

32. Lee IJ, Kim YI, Kim KW, et al. Radiofrequency ablation combined with transcatheter arterial embolisation in rabbit liver: investigation of the ablation zone according to the time interval between the two therapies. *Br J Radiol.* 2012;85(1019):e987–e994.

33. Xing Y, Zhao JH, Conti PS, Chen K. Radiolabeled nanoparticles for multimodality tumor imaging. *Theranostics.* 2014;4(3):290–306.

34. Miyayama S, Matsu O, Yamashiro M, et al. Ultrasensitive transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. *J Vasc Interv Radiol.* 2007;18(3):365–376.

35. Di Martin M, Marin D, Guerrisi A, et al. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis. *Radiology.* 2010;256(3):806–816.

36. De Santis M, Alborino S, Tartoni PL, Torricelli P, Casolo A, Romagnoli R. Effects of lipiodol retention on MRI signal intensity from hepatocellular carcinoma and surrounding liver treated by chemoembolization. *Eur Radiol.* 1997;7(1):10–16.